Pharmacogénétique de l'Imatinib dans la Leucémie Myéloïde Chronique etDonnées Censurées par Intervalles en présence de Compétition

Pharmacogénétique de l'Imatinib dans la Leucémie Myéloïde Chronique etDonnées Censurées par Intervalles en présence de Compétition

Le traitement de la leucémie myéloïde chronique (LMC) par imatinib est un succès de thérapie ciblée en oncologie. Le principe de cette thérapie est de bloquer les processus biochimiques à l'origine du développement de la maladie, et de permettre à une majorité de patients de réduire leurs risqu...

Full description

Bibliographic Details
Main Author:	Delord, Marc
Other Authors:	Université Paris-Saclay (ComUE)
Language:	fr
Published:	2015
Subjects:	Leucémie myéloïde chronique Imatinib Pharmacogénétique Niveau de preuve Imputation multiple Censure par intervalles informative Chronic myeloid leukemia Pharmacogenetics Level of evidence Multiple imputation Informative interval censoring
Online Access:	http://www.theses.fr/2015SACLS075/document

Similar Items

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

Hematologic Relapse after 2 Years on a Non-Authorized Copy Version of Imatinib in a Patient with Chronic Myeloid Leukemia in Chronic Phase: A Case Report
by: Zoubir Chouffai
Published: (2010-07-01)

Survival of Patients with CML on Imatinib Experience with 44 Iraqi Patients
by: Ali M. Jawad, et al.
Published: (2008-10-01)

Nilotinib therapy after resistance and intolerance to imatinib in CML patient with trisomy of the chromosome 8
by: Antonella Russo Rossi
Published: (2015-10-01)

Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome
by: Massimo Breccia
Published: (2015-10-01)

Efficacy of nilotinib therapy in patient with CML diagnosed in pre-TKI era and resistant to imatinib
by: Ivana Pierri, et al.
Published: (2015-10-01)

Nilotinib therapy after resistance to imatinib
by: Raffaele Porrini, et al.
Published: (2015-10-01)

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
by: Frédéric Millot, et al.
Published: (2021-08-01)

O tratamento da Leucemia Mielóide Crônica com mesilato de imatinibe Therapy of Chronic Myeloid Leukemia with imatinib mesylate
by: Vaneuza M. Funke, et al.
Published: (2008-04-01)

Is imatinib still the best choice as first-line oral TKI
by: Shweta Bansal
Published: (2014-01-01)

OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)

Tyrosine kinase inhibitor treatment outcome in a single center cohort of chronic myeloid leukemia patients. The role of the T315I ABL kinase domain mutation
by: Dima Delia, et al.
Published: (2013-03-01)

Nilotinib after imatinib failure
by: Luca Pezzullo
Published: (2015-10-01)

Chronic Myeloid Leukemia with Variant Chromosomal Translocations: Results of Treatment with Imatinib Mesylate
by: Rohan Bhise, et al.
Published: (2013-01-01)

Renal phosphate loss in Iraqi chronic myeloid leukemia patients treated by imatinib mesylate
by: Huda A Al-Taee, et al.
Published: (2020-01-01)

Uncontrolled neovascular glaucoma – an alarming manifestation of chronic myeloid leukemia on imatinib therapy – a case report and review of literature
by: Prakhyat Roop, et al.
Published: (2019-01-01)

Reacciones adversas del imatinib como droga de segunda línea en pacientes con leucemia mieloide crónica Adverse reactions to imatinib as second-line drug in patients with chronic myeloid leukemia
by: Onel M. Ávila Cabrera, et al.
Published: (2010-12-01)

Relationship between Oxidative Stress and Imatinib Resistance in Model Chronic Myeloid Leukemia Cells
by: Sylwester Głowacki, et al.
Published: (2021-04-01)

Outcome of young adults with chronic myeloid leukemia treated with upfront imatinib: A single institutional experience
by: Govind K Babu, et al.
Published: (2015-01-01)

Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea
by: Parveen Jain, et al.
Published: (2013-01-01)

Comparison of effectiveness and safety of Iranian-made vs. Indian-made imatinib in treatment of chronic myeloid leukemia
by: Kamran Moshfeghi, et al.
Published: (2013-01-01)

Caffeic Acid Enhances the Anti-Leukemic Effect of Imatinib on Chronic Myeloid Leukemia Cells and Triggers Apoptosis in Cells Sensitive and Resistant to Imatinib
by: Giordana Feriotto, et al.
Published: (2021-02-01)

Different response to imatinib and nilotinib in relationship with the time of administration
by: Paolo Danise
Published: (2015-10-01)

Efficacy of nilotinib in a patient relapse after 9 years of imatinib treatment and in stable complete cytogenetic response
by: Marzia Defina
Published: (2015-10-01)

Imatinib plus Granulocyte Colony-Stimulating Factor in Chronic Myeloid Leukemia Patients Who Have Achieved Partial or Complete Cytogenetic Response while on Imatinib
by: Baijun Fang, et al.
Published: (2011-04-01)

Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience
by: Wael Abdelgawad Edesa, et al.
Published: (2015-06-01)

Imatinib en leucemia mieloide crónica Imatinib in chronic myeloid leukemia
by: Valia Pavón Morán, et al.
Published: (2005-12-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

OUR EXPERIENCE IN TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Marjana Glaser, et al.
Published: (2004-04-01)

Complete molecular response induced by nilotinib in a patient previously treated with imatinib, nilotinib and dasatinib
by: Giuseppe Pietrantuono
Published: (2015-10-01)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
by: Katerina Arvaniti, et al.
Published: (2014-07-01)

Leucemia Mielóide Crônica: causas de falha do tratamento com mesilato de imatinibe Chronic Myeloid Leukemia: causes of treatment failure with imatinib
by: Katia B. B. Pagnano
Published: (2008-04-01)

Chronic subdural hematoma-unsual cause of headache in a patient with chronic myeloid leukemia treated with high-dose imatinib mesylate: A rare case report with review of literature
by: Sanjay M Khaladkar, et al.
Published: (2015-01-01)

Mutations Associated with Imatinib Mesylate Resistance - Review
by: Linev Alexandar J., et al.
Published: (2018-12-01)

Nilotinib efficacy in a patient resistant to imatinib
by: Luigia Luciano
Published: (2015-10-01)

Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up
by: Mozafar Aznab, et al.
Published: (2021-01-01)

Imatinib resistance was reversed by nilotinib in the acute transformation of chronic myeloid leukemia: A case report
by: Meng Xiao, et al.
Published: (2017-12-01)

The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients
by: Petra Belohlavkova, et al.
Published: (2018-02-01)

Single Center Study of Prescribing and Treatment Outcomes of Patients with Chronic Myeloid Leukemia
by: Ladan Nekoohesh, et al.
Published: (2020-01-01)

Cannot write session to /tmp/vufind_sessions/sess_lp2p1kqmus387dmak2s330g94o